GemVax & KAEL Co.,Ltd. Logo

GemVax & KAEL Co.,Ltd.

Makes contamination controls for semiconductors & develops Alzheimer's therapeutics.

082270 | KO

Overview

Corporate Details

ISIN(s):
KR7082270000
LEI:
Country:
South Korea
Address:
대전광역시 유성구 테크노11로 58, 대전광역시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

GemVax & KAEL Co., Ltd. is a company with a dual-business structure. Its Environmental Control division manufactures and sells contaminant control solutions, including coating resins and filters, for the semiconductor and display industries. This established business provides the financial foundation for its Bio division, a clinical-stage biopharmaceutical arm focused on developing novel therapeutics. The Bio division's lead candidate is GV1001, a telomerase-derived peptide being developed as a treatment for neurodegenerative diseases, including Alzheimer's disease and Progressive Supranuclear Palsy, and is advancing into late-stage clinical trials.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-17 00:00
Major Shareholding Notification
[기재정정]최대주주변경을수반하는주식담보제공계약체결
Korean 47.6 KB
2025-09-16 00:00
Share Issue/Capital Change
주요사항보고서(제3자의신주인수권부사채매수선택권행사)
Korean 19.5 KB
2025-09-12 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 163.1 KB
2025-09-12 00:00
Registration Form
[기재정정]증권신고서(지분증권) (2025.11)
Korean 3.3 MB
2025-09-05 00:00
Major Shareholding Notification
[기재정정]최대주주변경을수반하는주식담보제공계약체결
Korean 50.6 KB
2025-09-02 00:00
Report Publication Announcement
기업설명회(IR)개최
Korean 6.8 KB
2025-08-29 00:00
Share Issue/Capital Change
주요사항보고서(유상증자결정)
Korean 30.2 KB
2025-08-29 00:00
Registration Form
[정정제출요구]증권신고서(지분증권) (2025.11)
Korean 2.9 MB
2025-08-22 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 163.3 KB
2025-08-18 00:00
Major Shareholding Notification
[기재정정]최대주주변경을수반하는주식담보제공계약체결
Korean 51.8 KB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.8 MB
2025-08-14 00:00
Major Shareholding Notification
[기재정정]최대주주변경을수반하는주식담보제공계약체결
Korean 50.7 KB
2025-08-04 00:00
Major Shareholding Notification
[기재정정]최대주주변경을수반하는주식담보제공계약체결
Korean 51.8 KB
2025-07-21 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.3 KB
2025-07-21 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.4 KB

Automate Your Workflow. Get a real-time feed of all GemVax & KAEL Co.,Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for GemVax & KAEL Co.,Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for GemVax & KAEL Co.,Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Apellis Pharmaceuticals, Inc. Logo
Developing novel C3 therapies for diseases in ophthalmology, nephrology, and hematology.
United States of America
APLS
Apimeds Pharmaceuticals US, Inc. Logo
Biopharma developing non-narcotic bee venom therapies for osteoarthritis pain and inflammation.
United States of America
APUS
Apogee Therapeutics, Inc. Logo
Developing novel antibody biologics for immunological and inflammatory (I&I) diseases.
United States of America
APGE
Apollomics Inc. Logo
A clinical-stage biopharma developing targeted oncology therapies for hard-to-treat cancers.
United States of America
APLM
Apontis Pharma AG Logo
German pharma firm specializing in Single Pills for cardiovascular and chronic diseases.
Germany
APPH
Develops DNA tech for genetic medicine, molecular diagnostics, and supply chain security.
United States of America
APDN
Applied Therapeutics, Inc. Logo
Develops treatments for rare metabolic and central nervous system (CNS) disorders.
United States of America
APLT
Aprea Therapeutics, Inc. Logo
Developing precision cancer therapies targeting DNA Damage Response for solid tumors.
United States of America
APRE
AprilBio Co.,Ltd. Logo
Develops long-acting biologic drugs for autoimmune diseases and oncology using its SAFA™ platform.
South Korea
397030
Aprogen Biologics Inc. Logo
Develops and manufactures novel biologic drugs and biosimilars for the professional market.
South Korea
003060

Talk to a Data Expert

Have a question? We'll get back to you promptly.